Excited to announce that our latest research for SIG-1273™ and AgeIQ™ has been published in the Journal of Cosmetic Dermatology. We demonstrate that SIG-1273™ has anti-pollution properties and.
Gizmodo released an article last Friday on SIG-1459 following up on the anti-acne story after the release of the New Scientist article earlier that week. We are so happy to see such a big response to.
Last week we had two big articles written on the effects of our new compound SIG-1459 on acne, and we couldn't be more excited!
Signum presented new anti-pollution data for SIG-1273 and anti-aging benefits of Age IQ™ at the International Investigative Dermatology Conference March 16-19 in Orlando, Florida. This conference.
We presented at this years Society of Investigative Dermatology Conference held in Portland, Oregon. The annual meeting covers not only basic science, but also emergent clinical and translational.
Signum Biosciences, INC. will be attending this years BIO International Convention in San Diego, California.
Dr. Jose Fernandez represented Signum Biosciences at this years DDRI Conference. He presented a poster"From Consumer Products to Drugs: Developing Novel Technologies in Dermatology and Neurology" .
SIG-990 aka ( DMT210) has entered into a Phase 2 Acne Rosacea Study conducted by our Dermata Therapeutics, LLC
Jan 31, 2017
Exciting news regarding our licensee, Dermata Therapeutics, LLC, a biotechnology company developing new and innovative products to treat a variety of dermatological diseases, announces dosing the.
Signum's lead Rx molecule SIG990 (DMT210) for Rosacea, it reduces redness and bumps in rosacea subjects.
Sep 29, 2016
Dermata Therapeutics, LLC Announces Positive Top-line Results from their Phase 1 Pharmacokinetic Study of DMT210 in Acne Rosacea Patients. Click here to see Dermata's Press release. DMT210 is an IPC.